These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28855795)

  • 41. Complement component 1Q (C1Q) upregulation in retina of murine, primate, and human glaucomatous eyes.
    Stasi K; Nagel D; Yang X; Wang RF; Ren L; Podos SM; Mittag T; Danias J
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):1024-9. PubMed ID: 16505037
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis of complement factor H by retinal pigment epithelial cells is down-regulated by oxidized photoreceptor outer segments.
    Chen M; Forrester JV; Xu H
    Exp Eye Res; 2007 Apr; 84(4):635-45. PubMed ID: 17292886
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.
    Yu RZ; Zhang H; Geary RS; Graham M; Masarjian L; Lemonidis K; Crooke R; Dean NM; Levin AA
    J Pharmacol Exp Ther; 2001 Feb; 296(2):388-95. PubMed ID: 11160622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung.
    Uemura Y; Hagiwara K; Kobayashi K
    PLoS One; 2017; 12(11):e0187286. PubMed ID: 29107995
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Study of CRTC2 pharmacology using antisense oligonuceotides.
    Dullea R; Salatto C; Sciabola S; Chen T; Dimattia D; Gandhok H; Kreeger J; Weng Y; Clark T; Vage C; Stanton R
    Nucleic Acid Ther; 2014 Apr; 24(2):127-38. PubMed ID: 24380393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.
    Henry SP; Giclas PC; Leeds J; Pangburn M; Auletta C; Levin AA; Kornbrust DJ
    J Pharmacol Exp Ther; 1997 May; 281(2):810-6. PubMed ID: 9152389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
    Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
    Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complement factor C3a alters proteasome function in human RPE cells and in an animal model of age-related RPE degeneration.
    Ramos de Carvalho JE; Klaassen I; Vogels IM; Schipper-Krom S; van Noorden CJ; Reits E; Gorgels TG; Bergen AA; Schlingemann RO
    Invest Ophthalmol Vis Sci; 2013 Oct; 54(10):6489-501. PubMed ID: 23982842
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro and in vivo inhibition of interleukin (IL)-5-mediated eosinopoiesis by murine IL-5Ralpha antisense oligonucleotide.
    Lach-Trifilieff E; McKay RA; Monia BP; Karras JG; Walker C
    Am J Respir Cell Mol Biol; 2001 Feb; 24(2):116-22. PubMed ID: 11159044
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
    Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
    J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats.
    Ponnappa BC; Dey I; Tu GC; Zhou F; Aini M; Cao QN; Israel Y
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1129-36. PubMed ID: 11356938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals.
    Swayze EE; Siwkowski AM; Wancewicz EV; Migawa MT; Wyrzykiewicz TK; Hung G; Monia BP; Bennett CF
    Nucleic Acids Res; 2007; 35(2):687-700. PubMed ID: 17182632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice.
    Liang Y; Osborne MC; Monia BP; Bhanot S; Watts LM; She P; DeCarlo SO; Chen X; Demarest K
    Metabolism; 2005 Jul; 54(7):848-55. PubMed ID: 15988691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antisense oligonucleotide inhibits the expression of procollagen type III gene in mouse fibroblasts.
    Kitamura Y; Tanigawa T; Nanba E; Ueno E; Fukumoto S; Ichihara K
    Biochem Biophys Res Commun; 1995 Oct; 215(3):849-54. PubMed ID: 7488051
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.
    Klasa RJ; Bally MB; Ng R; Goldie JH; Gascoyne RD; Wong FM
    Clin Cancer Res; 2000 Jun; 6(6):2492-500. PubMed ID: 10873104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2.
    Ravichandran K; Ozkok A; Wang Q; Mullick AE; Edelstein CL
    Am J Physiol Renal Physiol; 2015 Feb; 308(4):F349-57. PubMed ID: 25537744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.
    Monteith DK; Geary RS; Leeds JM; Johnston J; Monia BP; Levin AA
    Toxicol Sci; 1998 Dec; 46(2):365-75. PubMed ID: 10048140
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Zinc supplementation inhibits complement activation in age-related macular degeneration.
    Smailhodzic D; van Asten F; Blom AM; Mohlin FC; den Hollander AI; van de Ven JP; van Huet RA; Groenewoud JM; Tian Y; Berendschot TT; Lechanteur YT; Fauser S; de Bruijn C; Daha MR; van der Wilt GJ; Hoyng CB; Klevering BJ
    PLoS One; 2014; 9(11):e112682. PubMed ID: 25393287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polyethyleneimine grafted with pluronic P85 enhances Ku86 antisense delivery and the ionizing radiation treatment efficacy in vivo.
    Belenkov AI; Alakhov VY; Kabanov AV; Vinogradov SV; Panasci LC; Monia BP; Chow TY
    Gene Ther; 2004 Nov; 11(22):1665-72. PubMed ID: 15470482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.